题：年诊疗量超16亿人次！中医药法护航"中华瑰宝" 超16亿人次！这是初步统计的2024年全国医疗卫生机构中医类总诊疗量，也是自2017年7月1日《中华人 民共和国中医药法》施行以来，中医药事业发展的一个生动注脚。 受益于这部法律，中医药事业和产业蓬勃发展，给群众带来实实在在的健康获得感。 中医药服务更加普惠可及—— 武汉市硚口区，11家社区卫生服务中心全部设置了中医诊室、中药房、中医健康教育室，配备了中药煎 药机、腰椎治疗牵引床、电热低频治疗仪等中医诊疗设备，还成立了多个中医药专家工作室，让群众 在"家门口"就能看上好中医。 随着中医药服务网络延伸、服务能力提升，中医诊疗量明显增长。国家中医药管理局监测统计中心初步 统计显示，2024年全国医疗卫生机构中医类总诊疗量超16亿人次，较2023年明显增长。仅在中国中医科 学院广安门医院，今年1月至5月的日均诊疗量就超过一万人次。 国务院办公厅发文加快提升中药质量、促进中医药产业高质量发展，中医药健康促进行动被纳入健康中 国行动……今年以来，以中医药法为"纲"的重磅政策密集出台，彰显着中医药在我国卫生健康事业中的 重要角色，推动着中医药更好发挥其在维护和促进人民健 ...

Core Insights - The 2025 Wuzhen Health Conference recognized Tianshili (600535.SH) as a VIP strategic partner and awarded its products for innovation and popularity in the retail market [1] - The Chinese pharmaceutical retail market is projected to reach 501.9 billion yuan in 2024, driven by policy changes and demographic shifts [3] - Tianshili focuses on integrating traditional Chinese medicine with modern medical practices, targeting major disease areas such as cardiovascular, digestive, oncology, and central nervous system disorders [3][8] Company Strategy - Tianshili is transitioning from high-quality products to strong brand recognition, emphasizing a digital marketing system centered on health value [4] - The company employs various promotional strategies, including social media campaigns and educational initiatives, to enhance brand visibility and consumer engagement [5] - Tianshili collaborates with offline strategic partners to create specialized health centers, improving customer service and market penetration [7] Product Performance - In 2024, Tianshili's traditional Chinese medicine segment generated 6.024 billion yuan, with key products like Compound Danshen Dripping Pills and Yangxue Qingnao Granules showing significant sales growth [7] - The company has a robust pipeline for cardiovascular drugs, with ongoing clinical trials for 17 modern Chinese medicine products [10] - Tianshili's innovative products, such as Shao Ma Zhi Jiao Granules and Kun Xin Ning Granules, have received recognition in clinical guidelines, enhancing its market position [10] Innovation and Responsibility - Tianshili emphasizes the integration of modern technology with traditional Chinese medicine to enhance product efficacy and market competitiveness [8] - The company aims to create a three-dimensional innovation system that combines clinical value, digital technology, and patient services [10] - Tianshili's commitment to innovation is reflected in its continuous development of new products and improvement of existing ones, ensuring long-term sustainability [10]